CRISPR Therapeutics AG (NASDAQ:CRSP) and Acer Therapeutics Inc. (NASDAQ:ACER) compete with each other in the Biotechnology sector. We will analyze and compare their institutional ownership, profitability, risk, analyst recommendations, dividends, earnings and valuation.

Valuation & Earnings

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
CRISPR Therapeutics AG 60 0.00 34.37M -0.46 0.00
Acer Therapeutics Inc. 3 0.00 3.46M -3.25 0.00

We can see in table 1 the earnings per share, gross revenue and valuation of CRISPR Therapeutics AG and Acer Therapeutics Inc.

Profitability

Table 2 demonstrates the net margins, return on equity and return on assets of CRISPR Therapeutics AG and Acer Therapeutics Inc.

Net Margins Return on Equity Return on Assets
CRISPR Therapeutics AG 57,388,545.67% -2.6% -2%
Acer Therapeutics Inc. 101,493,062.69% -98.3% -87.3%

Liquidity

The current Quick Ratio of CRISPR Therapeutics AG is 8.3 while its Current Ratio is 8.3. Meanwhile, Acer Therapeutics Inc. has a Current Ratio of 7.1 while its Quick Ratio is 7.1. CRISPR Therapeutics AG is better positioned to pay off its short-term and long-term debts than Acer Therapeutics Inc.

Analyst Ratings

Recommendations and Ratings for CRISPR Therapeutics AG and Acer Therapeutics Inc. can be find in next table.

Sell Ratings Hold Ratings Buy Ratings Rating Score
CRISPR Therapeutics AG 0 0 3 3.00
Acer Therapeutics Inc. 0 0 0 0.00

CRISPR Therapeutics AG’s upside potential is 10.16% at a $72 average price target.

Insider and Institutional Ownership

Institutional investors owned 46.8% of CRISPR Therapeutics AG shares and 55.1% of Acer Therapeutics Inc. shares. About 0.4% of CRISPR Therapeutics AG’s share are owned by insiders. Insiders Competitively, owned 0.2% of Acer Therapeutics Inc. shares.

Performance

Here are the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
CRISPR Therapeutics AG 1% 49.37% 59.3% 63.07% 101.48% 153.31%
Acer Therapeutics Inc. 5.46% 13.62% 26.12% -77.4% -82.52% -81.76%

For the past year CRISPR Therapeutics AG has 153.31% stronger performance while Acer Therapeutics Inc. has -81.76% weaker performance.

Summary

CRISPR Therapeutics AG beats on 8 of the 10 factors Acer Therapeutics Inc.

CRISPR Therapeutics AG, a gene editing company, focuses on developing transformative gene-based medicines for the treatment of serious human diseases using its proprietary clustered, regularly interspaced short palindromic repeats associated protein-9 (CRISPR/Cas9)gene-editing platform in Switzerland. The CRISPR/Cas9 technology allows for changes to genomic DNA. It has a collaboration agreement with Vertex Pharmaceuticals, Incorporated to develop, manufacture, commercialize, sell, and use therapeutics; a license agreement with Anagenesis Biotechnologies SAS; and a service agreement with MaSTherCell SA to develop and manufacture allogeneic CAR-T therapies. The company also has research collaboration agreements with Neon Therapeutics and Massachusetts General Hospital Cancer Center to develop novel T cell therapies for cancer. CRISPR Therapeutics AG is headquartered in Basel, Switzerland.

Acer Therapeutics Inc. develops therapies for the treatment of serious ultra-rare diseases with critical unmet medical needs. The company offers Celiprolol for vascular ehlers-danlos syndrome and ACER-001 for maple syrup urine disease (MSUD). It also offers advancing ACER-001 for the treatment of urea cycle disorders (UCD). The company was founded in 2013 and is based in Cambridge, Massachusetts.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.



Source link